Who is sponsoring NCT05728788?

NCT05728788 is sponsored by Peking University Third Hospital.

What drugs are being tested in NCT05728788?

Interventions in NCT05728788: Antitumor drugs.

What condition does NCT05728788 study?

NCT05728788 studies Cancer Therapy-related Cardiovascular Toxicity.

Is NCT05728788 still recruiting?

NCT05728788 is currently status unknown. Last updated 3 March 2023.

Last reviewed 2023-03-03 · How we verify

NCT05728788

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy

Status unknown Last updated 3 March 2023

What this trial tests

trial testing Antitumor drugs in Cancer Therapy-related Cardiovascular Toxicity in 50 participants. Status unknown.

Timeline

1 July 2022

Primary endpoint
1 June 2023

1 December 2023

Quick facts

Lead sponsor	Peking University Third Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 July 2022
Primary completion	1 June 2023
Estimated completion	1 December 2023
Sites	1 location across China

Drugs / interventions tested

Antitumor drugs — full drug profile →

Conditions studied

Cancer Therapy-related Cardiovascular Toxicity — all drugs for Cancer Therapy-related Cardiovascular Toxicity →

Sponsor

Peking University Third Hospital

Who can join

Adults 18 to 75, any sex, with Cancer Therapy-related Cardiovascular Toxicity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to explore the relationship between early myocardial injury caused by tumor drug therapy and intestinal microbial structure changes by echocardiographic two-dimensional speckle tracking technique and intestinal microflora structure detection.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Changes in Intestinal Flora and Serum Metabolites Pre- and Post-Antitumor Drug Therapy in Patients with Non-Small Cell Lung Cancer.
Tian Z, Liu Y, Zhu D, Cao B, et al · · 2024 · cited 2× · PMID 38256661 · DOI 10.3390/jcm13020529

Verify or expand the search:

Other Peking University Third Hospital trials

Trials by the same sponsor.

NCT07532421 — Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life · NA · not yet recruiting
NCT07470255 — Detection of Diabetic Foot Skin Damage Using Plantar Mechanical Parameters · not yet recruiting
NCT07453381 — Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA/INOCA Patients: A Prospective · not yet recruiting
NCT07452354 — AI-Based Diabetic Foot Recurrence Cohort · not yet recruiting
NCT07423819 — Sports Rehabilitation Therapy for Knee Joint Sports Injuries: A Case Study of Anterior Cruciate Ligament Injury and Pate · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05728788 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University Third Hospital
Last refreshed: 3 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05728788.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing